Ramreddy Godela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ramreddy Godela has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Krishnaphanisri Ponnekanti
Malla Reddy Institute of Pharmaceutical Science, Malla Reddy Vishwavidyapeeth, Hyderabad, India
3 shared publicationsKranthi Kumar Pola
Joginpally B.R Pharmacy College, Hyderabad, Telangana, India
2 shared publicationsSowjanya G
GITAM Institute of Pharmacy, GITAM Deemed to be University, Visakhapatnam, India, 530045
2 shared publicationsSowjanya Gummadi
GITAM Institute of Pharmacy, GITAM Deemed to be University, Visakhapatnam, India
2 shared publicationsDivya Reddy Solipeta
Gitam School of Pharmacy, Gitam Deemed to be University, Hyderabad, India
1 shared publicationDurga Prasad Beda
Gitam School of Pharmacy, Gitam Deemed to be University, Hyderabad, India
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by Springer Nature in BMC Chemistry
- Vol. 20 (1)
AQbD Driven RP-HPLC method for estimating rizatriptan benzoate and meloxicam: integrating green and blue analytical approaches
- 13 August 2026
- Published by Springer Nature in BMC Chemistry
- Vol. 20 (1)
Open AccessAQbD Driven RP-HPLC method for estimating rizatriptan benzoate and meloxicam: integrating green and blue analytical approaches
- 4 January 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 91
RP-HPLC Method for Simultaneous Estimation of Sulopenem Etzadroxil and Probenecid: Incorporating Design of Experiment and Green Metrics
- 4 January 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 91
RP-HPLC Method for Simultaneous Estimation of Sulopenem Etzadroxil and Probenecid: Incorporating Design of Experiment and Green Metrics
- Open Access
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 465-470
STABILITY INDICATING LC–ESI-MS/MS METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTITATION OF LURBINECTEDIN IN BIOLOGICAL MATRICES
Objective: A new and validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and used for the quantitative analysis of the anticancer drug Lurbinectedin in plasma samples. Methods: Liquid-liquid extraction method was used to extract the Lurbinectedin from plasma, and Ledipasvir was used as an internal standard (IS), Chromatographic separation of Lurbinectedin was accomplished with Zorbax SB-C18 column (250 mm×4.6 mm, 5 µm) using a mobile phase comprises of 0.1% v/v formic acid and acetonitrile (10:90, v/v) pumped at a flow rate of 0.80 ml/min. The total run time for Lurbinectedin and internal standard elution was 3.5 min. The linearity was attained for a concentration range of 1.50–5000 ng/ml with a correlation coefficient (r²) of 0.9994 by the optimized method. The lower limit of quantification (LLOQ) was established at 1.50 ng/ml, which resembles the sensitivity of the method toward Lurbinectedin. Results: The method showed high accuracy, ranging from 95.31% to 104.06% of nominal values, with intra-and inter-day precision within a 4.32% coefficient of variance (%CV). Matrix effects at the low-quality control (LQC) level varied between 94.25% and 104.85% (%CV: 4.61), while at the high-quality control (HQC) level, they ranged from 94.62% to 103.88% (%CV: 4.02). The mean recovery across all control standards was 95.58%. Conclusion: Stability assessments confirmed the robustness of the method. The developed LC-MS/MS approach is reliable for routine bioanalytical applications, including quality control, pharmacokinetic studies, and bioequivalence assessments of Lurbinectedin in biological matrices.
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 465-470
Open AccessSTABILITY INDICATING LC–ESI-MS/MS METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTITATION OF LURBINECTEDIN IN BIOLOGICAL MATRICES
Objective: A new and validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and used for the quantitative analysis of the anticancer drug Lurbinectedin in plasma samples. Methods: Liquid-liquid extraction method was used to extract the Lurbinectedin from plasma, and Ledipasvir was used as an internal standard (IS), Chromatographic separation of Lurbinectedin was accomplished with Zorbax SB-C18 column (250 mm×4.6 mm, 5 µm) using a mobile phase comprises of 0.1% v/v formic acid and acetonitrile (10:90, v/v) pumped at a flow rate of 0.80 ml/min. The total run time for Lurbinectedin and internal standard elution was 3.5 min. The linearity was attained for a concentration range of 1.50–5000 ng/ml with a correlation coefficient (r²) of 0.9994 by the optimized method. The lower limit of quantification (LLOQ) was established at 1.50 ng/ml, which resembles the sensitivity of the method toward Lurbinectedin. Results: The method showed high accuracy, ranging from 95.31% to 104.06% of nominal values, with intra-and inter-day precision within a 4.32% coefficient of variance (%CV). Matrix effects at the low-quality control (LQC) level varied between 94.25% and 104.85% (%CV: 4.61), while at the high-quality control (HQC) level, they ranged from 94.62% to 103.88% (%CV: 4.02). The mean recovery across all control standards was 95.58%. Conclusion: Stability assessments confirmed the robustness of the method. The developed LC-MS/MS approach is reliable for routine bioanalytical applications, including quality control, pharmacokinetic studies, and bioequivalence assessments of Lurbinectedin in biological matrices.
- 5 September 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (9) , 4225-4231
Analytical Quality by Design Based Robust RP-HPLC Method for Estimation of Setracanozole in Bulk and Tablet Formulation-Method Development and Validation
The key aim of the stated research was to develop and validate robust, sensitive, simple RP-HPLC with enhanced performance for estimating Setracanozole in API powder and tablet formulation by implementing analytical quality by-design studies. The method was optimized by the central composite design of the response surface study. Successful separation of Setracanozole was obtained using C18 (250 x 4.6mm, 5µ column and a mobile phase of methanol: 0.1% v/v formic acid (90:10) with 1.0ml/min flow rate. The separated Setracanozole and its degradants were explored with a UV detector at 245nm. The RT of Setracanozole was observed to be 4.2min. The approach was validated per ICH, proving it was more sensitive, precise, accurate, and specific. The lowest concentration of Setracanozole’s limit of detection and quantification makes guarantees regarding the method's sensitivity. For the provided range of linear concentrations (2.5 to 30µg/ml), the regression coefficient was found to be 0.999. The computed average percentage recoveries of Setracanozole in spiked solutions ranged from 99.1 to 101.75%. The % degradation of Setracanozole in various forced conditions confirmed the existing method's stability. Setracanozole was significantly sensitive to base hydrolysis when compared to other stressful conditions such as Acid hydrolysis, thermal degradation, and photodegradation. The proposed HPLC approach separated Setracanozole with high sensitivity, a short retention time, and an affordable solvent system. As a result, the proposed method can be used in the pharmaceutical industry.
- 5 September 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (9) , 4225-4231
Analytical Quality by Design Based Robust RP-HPLC Method for Estimation of Setracanozole in Bulk and Tablet Formulation-Method Development and Validation
The key aim of the stated research was to develop and validate robust, sensitive, simple RP-HPLC with enhanced performance for estimating Setracanozole in API powder and tablet formulation by implementing analytical quality by-design studies. The method was optimized by the central composite design of the response surface study. Successful separation of Setracanozole was obtained using C18 (250 x 4.6mm, 5µ column and a mobile phase of methanol: 0.1% v/v formic acid (90:10) with 1.0ml/min flow rate. The separated Setracanozole and its degradants were explored with a UV detector at 245nm. The RT of Setracanozole was observed to be 4.2min. The approach was validated per ICH, proving it was more sensitive, precise, accurate, and specific. The lowest concentration of Setracanozole’s limit of detection and quantification makes guarantees regarding the method's sensitivity. For the provided range of linear concentrations (2.5 to 30µg/ml), the regression coefficient was found to be 0.999. The computed average percentage recoveries of Setracanozole in spiked solutions ranged from 99.1 to 101.75%. The % degradation of Setracanozole in various forced conditions confirmed the existing method's stability. Setracanozole was significantly sensitive to base hydrolysis when compared to other stressful conditions such as Acid hydrolysis, thermal degradation, and photodegradation. The proposed HPLC approach separated Setracanozole with high sensitivity, a short retention time, and an affordable solvent system. As a result, the proposed method can be used in the pharmaceutical industry.
- Open Access
- 15 May 2025
- Published by Springer Nature in Discover Applied Sciences
- Vol. 7 (5) , 1-13
A novel RP-HPLC stability-indicating method for simultaneous estimation of Niraparib and Abiraterone in synthetic mixtures and combined tablet formulations
- 15 May 2025
- Published by Springer Nature in Discover Applied Sciences
- Vol. 7 (5) , 1-13
Open AccessA novel RP-HPLC stability-indicating method for simultaneous estimation of Niraparib and Abiraterone in synthetic mixtures and combined tablet formulations
- Open Access
- 20 November 2024
- Published by Springer Nature in Discover Applied Sciences
- Vol. 6 (12) , 1-14
Concurrent estimation of Pregabalin and Etoricoxib by new stability indicating RP-UPLC approach: application in assay of commercial tablets
- 20 November 2024
- Published by Springer Nature in Discover Applied Sciences
- Vol. 6 (12) , 1-14
Open AccessConcurrent estimation of Pregabalin and Etoricoxib by new stability indicating RP-UPLC approach: application in assay of commercial tablets
- 30 November 2023
- Published by Elsevier in Fitoterapia
- Vol. 172, 105764
Nardostachys jatamansi: Phytochemistry, ethnomedicinal uses, and pharmacological activities: A comprehensive review
- 30 November 2023
- Published by Elsevier in Fitoterapia
- Vol. 172, 105764
Nardostachys jatamansi: Phytochemistry, ethnomedicinal uses, and pharmacological activities: A comprehensive review
- 2 December 2022
- Published by Springer Nature in Chemistry Africa
- Vol. 6 (1) , 393-403
RP-HPLC–PDA Approach for Concurrent Analysis of Telmisartan and Azelnidipine in Bulk and Commercial Tablets
- 2 December 2022
- Published by Springer Nature in Chemistry Africa
- Vol. 6 (1) , 393-403
RP-HPLC–PDA Approach for Concurrent Analysis of Telmisartan and Azelnidipine in Bulk and Commercial Tablets
- 30 November 2021
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 14 (11) , 5913-5918
Concurrent Determination of Daclatasvir and Sofosbuvir in Pure Binary Mixture and Their Combined Film Coated Tablets by a Simple Stability Indicating RP-HPLC Method
- 30 November 2021
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 14 (11) , 5913-5918
Concurrent Determination of Daclatasvir and Sofosbuvir in Pure Binary Mixture and Their Combined Film Coated Tablets by a Simple Stability Indicating RP-HPLC Method